BioCentury | Apr 8, 2021
Distillery Therapeutics

Folate receptor-targeting CAR T for ovarian and other cancers

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer; melanoma; colorectal cancer CAR T cells targeting folate receptor FOLR2 could treat ovarian cancer, melanoma and colorectal cancer. Among patients with stage III or IV ovarian cancer, high FOLR2...
BioCentury | Apr 7, 2021
Distillery Therapeutics

eIF4E identified as target in obesity, fatty liver disease

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; liver disease Reducing levels of eIF4E or lowering the RNA cap-binding protein’s activity by blocking its phosphorylation could treat obesity...
BioCentury | Apr 7, 2021
Distillery Therapeutics

A targeted CDK12 degrader for ALL

DISEASE CATEGORY: Cancer INDICATION: Acute lymphoblastic leukemia (ALL) A CDK12-targeted degrader, designed by a Dana-Farber Cancer Institute and Harvard Medical School team co-led by Nathanael Gray, could treat T cell ALL. The degrader’s targeting moiety was derived...
BioCentury | Apr 6, 2021
Distillery Therapeutics

Herb-extracted compound triptonide identified as male contraceptive

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Contraception Triptonide, a compound purified from Tripterygium Wilfordii Hook F, could serve as a non-hormonal male contraceptive. In vitro assays identified JUP as triptonide’s most likely target. In mice and cynomolgus monkeys, oral triptonide led to...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

DISEASE CATEGORY: Cancer INDICATION: Melanoma; lung cancer A Yale University and Memorial Sloan Kettering Cancer Center team led by Arvinas Inc. (NASDAQ:ARVN) founder Craig Crews created a PROTAC based on Zelboraf vemurafenib that could treat BRAF...
BioCentury | Feb 23, 2021
Distillery Therapeutics

Endocytic protein SH3GL1 as an autoimmune arthritis target

DISEASE CATEGORY: Autoimmune INDICATION: Arthritis; rheumatoid arthritis (RA) Inhibiting the endocytic protein SH3GL1 could treat autoimmune arthritis, including RA. CD4+ T cells from eight RA patients had higher mRNA levels of SH3GL1 than cells from...
BioCentury | Feb 23, 2021
Distillery Therapeutics

CRISPR-Cas13a targeting of viral genes for COVID-19, flu

DISEASE CATEGORY: Infectious disease INDICATION: Coronavirus; influenza CRISPR-Cas13a knockdown of the nucleocapsid protein of SARS-CoV-2 or influenza’s viral RNA polymerase could treat COVID-19 or flu, respectively. In monkey kidney cells infected with SARS-CoV-2, Cas13a targeting of the...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Steroid sulfatase identified as target in aging-related diseases

DISEASE CATEGORY: Neurology INDICATION: Alzheimer's disease (AD); Huntington disease (HD); Parkinson's disease (PD) Inhibiting STS, which removes sulfates from inactive steroid hormones, could treat Alzheimer’s, Huntington and Parkinson’s diseases and other aging-related indications. In a  Caenorhabditis...
BioCentury | Jan 30, 2021
Distillery Therapeutics

Targeting the RAGE-LCP2 interaction for sepsis

DISEASE CATEGORY: Infectious disease INDICATION: Sepsis Disrupting the interaction between the immunoglobulin-like cell surface receptor RAGE and the adaptor protein LCP2 could treat sepsis. Immunoprecipitation assays revealed LCP2’s sterile α motif domain binds RAGE’s cytosolic tail. In...
BioCentury | Jan 29, 2021
Distillery Therapeutics

VEGF-A gene editing therapy to treat wet AMD

DISEASE CATEGORY: Ophthalmic disease INDICATION: Age-related macular degeneration (AMD) A CRISPR-Cas9-based lentiviral vector gene therapy targeting VEGF-A could prevent wet AMD. In a mouse model of laser-induced wet AMD, pretreatment with the gene therapy injected subretinally...
Items per page:
1 - 10 of 3074